News Articles for Liz Dallimore

Three Perth pharmaceutical companies will take a share of a $12 million funding injection by the federal government to develop Australian-made heart disease and diabetes treatments.

Perth-based neurological drug developer Argenica Therapeutics has been knocked back by the US Food and Drug Administration, dashing hopes its US clinical trials would soon start.

Shares in Argenica Therapeutics were down by 13 per cent on Friday morning, despite the biotechnology technology announcing it would raise $12 million in order to complete its second phase trial of its ARG 007 drug in ischaemic stroke patients.

Perth biotech company Argenica Therapeutics' drug, which is designed to reduce brain tissue death following a stroke, will be administrated at two local hospitals in a nationwide trial.

The state government has awarded $4.3 million to nine health and medical projects, including developing new therapy for liver cancer and delaying Alzheimer's disease progression.

The commercial side of life sciences may have reached a critical mass in WA.

Our weekly appointments wrap includes Lauren Major, Sean-Paul Stephens, Michael Lundberg, Ashwin Nair, Tom Chaney, David Cresp, Addy Wetzler, Alex Maund, Esme Bowen and Liz Dallimore.

Our board moves wrap includes Liz Dallimore, Errol Turner, Michael Jordon, Melissa Chapman, Catherine Grant-Edwards, Neil Hutchison, Steve Brockhurst, Karen O'Neill, Darryl Abotomey, Joe D'Addio, Kelly Moore, Jason Livingstone, Trevor Matthews, Bill McKenzie, Dougal Ferguson, and Sylvia Moss.

Our weekly appointment wrap includes Alex Jenkins, Natalie Sarich-Dayton, Nick O'Loughlin, Kathryn Penno, Martina Ellis and Jerome Lee.

A Perron Institute spinout focused on reducing brain damage caused by strokes listed on the ASX this morning, with its share price rising 50 per cent.

How should WA prepare for a productivity revolution driven by data science and machine learning?